The latest financial statement is for the quarter ending 2025-09-30.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net income (loss) | 10,325 | -4,621 |
| Stock-based compensation | 1,407 | 2,106 |
| Depreciation and amortization | 246 | 388 |
| Amortization of right-of-use assets | 83 | 185 |
| Allowance for credit losses | -19 | 131 |
| Loss on disposal and impairment of assets | -210 | - |
| Loss (gain) on extinguishment of debt | -477 | 0 |
| Change in fair value of derivative liabilities | -6,097 | 3,911 |
| Gain on sale of patents | 5,000 | - |
| Amortization of debt issuance costs and debt discounts | 354 | 1,062 |
| Gain on lease modification | 7 | - |
| Accrued interest and accrued interest, related party | 0 | 0 |
| Proceeds from tenant improvement funds | 157 | 429 |
| Accounts receivable | 737 | 650 |
| Inventory | 903 | 1,762 |
| Prepaid expenses and other assets | -222 | 1,231 |
| Accounts payable | -10 | 274 |
| Accrued expenses and contract liabilities | 452 | -746 |
| Operating lease payments | 79 | - |
| Net cash flows provided by operating activities | 1,081 | -524 |
| Purchase of property and equipment | 525 | 1,321 |
| Proceeds from sale of patents | 5,000 | - |
| Net cash flows provided by (used in) investing activities | 4,475 | -1,321 |
| Proceeds from secured term loan | 23,000 | - |
| Proceeds from secured revolving credit facility | 655 | - |
| Payment of debt issuance costs | 371 | - |
| Proceeds from exercises of stock options | 106 | 253 |
| Payment of note payable | 27,747 | 0 |
| Proceeds from convertible and promissory note payable-Nonrelated Party | 0 | 0 |
| Payments of principal on finance leases | - | 149 |
| Proceeds from convertible and promissory note payable-Related Party | 0 | 0 |
| Proceeds from factoring, net | 0 | 0 |
| Payments of principal on finance lease and extinguishment of lease liability | 242 | - |
| Net cash flows used in financing activities | -4,450 | 104 |
| Effect of exchange rates on cash | 0 | 0 |
| Net change in cash during period | 1,106 | -1,741 |
| Cash and cash equivalents at beginning of period | 10,237 | - |
| Cash and cash equivalents at end of period | 9,602 | - |
SANUWAVE Health, Inc. (SNWV)
SANUWAVE Health, Inc. (SNWV)